Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
Front Immunol. 2022 Dec 22;13:1059994. doi: 10.3389/fimmu.2022.1059994. eCollection 2022.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron damage. Due to the complexity of the ALS, so far the etiology and underlying pathogenesis of sporadic ALS are not completely understood. Recently, many studies have emphasized the role of inflammatory networks, which are comprised of various inflammatory molecules and proteins in the pathogenesis of ALS. Inflammatory molecules and proteins may be used as independent predictors of patient survival and might be used in patient stratification and in evaluating the therapeutic response in clinical trials. This review article describes the latest advances in various inflammatory markers in ALS and its animal models. In particular, this review discusses the role of inflammatory molecule markers in the pathogenesis of the disease and their relationship with clinical parameters. We also highlight the advantages and disadvantages of applying inflammatory markers in clinical manifestations, animal studies, and drug clinical trials. Further, we summarize the potential application of some inflammatory biomarkers as new therapeutic targets and therapeutic strategies, which would perhaps expand the therapeutic interventions for ALS.
肌萎缩侧索硬化症（ALS）是一种以进行性运动神经元损伤为特征的神经退行性疾病。由于 ALS 的复杂性，目前散发性 ALS 的病因和潜在发病机制尚不完全清楚。最近，许多研究强调了炎症网络的作用，炎症网络由 ALS 发病机制中的各种炎症分子和蛋白质组成。炎症分子和蛋白质可用作患者生存的独立预测因子，可能用于患者分层以及评估临床试验中的治疗反应。本文综述了 ALS 及其动物模型中各种炎症标志物的最新进展。特别是，本文讨论了炎症分子标志物在疾病发病机制中的作用及其与临床参数的关系。我们还强调了在临床症状、动物研究和药物临床试验中应用炎症标志物的优缺点。此外，我们总结了一些炎症生物标志物作为新的治疗靶点和治疗策略的潜在应用，这可能会扩展 ALS 的治疗干预措施。
